Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Payables (2022 - 2025)

Historic Payables for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $10.1 million.

  • NewAmsterdam Pharma's Payables fell 455.58% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 455.58%. This contributed to the annual value of $13.6 million for FY2024, which is 1958.87% down from last year.
  • Latest data reveals that NewAmsterdam Pharma reported Payables of $10.1 million as of Q3 2025, which was down 455.58% from $9.5 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Payables' 5-year high stood at $22.7 million during Q2 2023, with a 5-year trough of $8.0 million in Q1 2025.
  • Over the past 4 years, NewAmsterdam Pharma's median Payables value was $10.4 million (recorded in 2024), while the average stood at $13.0 million.
  • Its Payables has fluctuated over the past 5 years, first tumbled by 5510.92% in 2024, then tumbled by 455.58% in 2025.
  • NewAmsterdam Pharma's Payables (Quarter) stood at $18.9 million in 2022, then dropped by 10.35% to $16.9 million in 2023, then fell by 19.59% to $13.6 million in 2024, then dropped by 25.79% to $10.1 million in 2025.
  • Its Payables stands at $10.1 million for Q3 2025, versus $9.5 million for Q2 2025 and $8.0 million for Q1 2025.